BridgeMD
Tests treatment safety and results for Polycystic Ovary Syndrome (PCOS)
Official title Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS
ClinicalTrials.gov ID: NCT07242131
What this study is testing
What is Combined Oral Contraceptive (Ethinylestradiol 0.03 mg + Drospirenone 3 mg)?
Combined Oral Contraceptive (Ethinylestradiol 0.03 mg + Drospirenone 3 mg) is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for polycystic ovary syndrome (pcos).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This cross-sectional study aims to compare the effectiveness of oral contraceptives, oral progesterone (didrogesterone), and inositol in regulating menstrual cycles among women diagnosed with polycystic ovary syndrome (PCOS). PCOS is a common endocrine disorder affecting reproductive-aged women and is associated with menstrual irregularities, hyperandrogenism, and polycystic ovarian morphology.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 40, women only
You may be able to join if
- Female participants aged 18 to 40 years.
- Diagnosed with polycystic ovary syndrome (PCOS) according to the ESHRE/ASRM (Rotterdam) criteria (presence of at least two of the following...
- No significant comorbid systemic disease.
- Willingness to participate and ability to provide written informed consent.
- Regular follow-up availability for at least 6 months.
You likely can't join if
- Known hepatic, renal, cardiovascular, or endocrine disorders other than PCOS.
- Pregnancy or current use of hormonal therapy within the past 3 months.
- History of thromboembolic disease, breast cancer, or other contraindications to hormonal treatment.
- Inability to adhere to follow-up visits or treatment regimen.
- Severe cognitive or communication impairment that prevents proper consent or data collection.
- Known allergy or hypersensitivity to any component of the study drugs.
See the full eligibility criteria
- Female participants aged 18 to 40 years.
- Diagnosed with polycystic ovary syndrome (PCOS) according to the ESHRE/ASRM (Rotterdam) criteria (presence of at least two of the following: oligo/anovulation, clinical or biochemical hyperandrogenism, polycystic...
- No significant comorbid systemic disease.
- Willingness to participate and ability to provide written informed consent.
- Regular follow-up availability for at least 6 months.
- Known hepatic, renal, cardiovascular, or endocrine disorders other than PCOS.
- Pregnancy or current use of hormonal therapy within the past 3 months.
- History of thromboembolic disease, breast cancer, or other contraindications to hormonal treatment.
- Inability to adhere to follow-up visits or treatment regimen.
- Severe cognitive or communication impairment that prevents proper consent or data collection.
- Known allergy or hypersensitivity to any component of the study drugs.
- Participation in another treatment study within the past 3 months.
The study team makes the final eligibility decision.
Where it's taking place
- Izmir, Menemen, Turkey (Türkiye)
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 40 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Izmir, Menemen, Turkey (Türkiye). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.